MMDA-2 (2-methoxy-4,5-methylenedioxyamphetamine) is a psychedelic drug of the amphetamine class. It is closely related to MMDA and MDA. Alexander Shulgin was likely the first to synthesize MMDA-2. In his book '' PiHKAL'', the dose is listed as 25–50 mg, and the duration is listed as 8–12 hours. Shulgin reports that MMDA-2 produces effects such as enhanced

awareness Awareness is the state of being conscious of something. More specifically, it is the ability to directly know and perceive, to feel, or to be cognizant of events. Another definition describes it as a state wherein a subject is aware of some infor ...

empathy Empathy is the capacity to understand or feel what another person is experiencing from within their frame of reference, that is, the capacity to place oneself in another's position. Definitions of empathy encompass a broad range of social, co ...

, and visual facilitation and

distortion In signal processing, distortion is the alteration of the original shape (or other characteristic) of a signal. In communications and electronics it means the alteration of the waveform of an information-bearing signal, such as an audio signa ...

, as well as some

side effect In medicine, a side effect is an effect, whether therapeutic or adverse, that is secondary to the one intended; although the term is predominantly employed to describe adverse effects, it can also apply to beneficial, but unintended, consequence ...

s like

gastrointestinal upset Gastrointestinal diseases (abbrev. GI diseases or GI illnesses) refer to diseases involving the gastrointestinal tract, namely the oesophagus, stomach, small intestine, large intestine and rectum, and the accessory organs of digestion, the liver, ...

and

appetite loss Anorexia is a medical term for a loss of appetite. While the term in non-scientific publications is often used interchangeably with anorexia nervosa, many possible causes exist for a loss of appetite, some of which may be harmless, while others i ...

. He states that 30 mg is very similar to 80 mg of MDA, and also remarks that it would be impossible for anyone to have a bad experience on the drug at that dose. Scientific research has shown that MMDA-2, unlike MMDA, but similarly to 6-methyl-MDA, is only very weak at inducing the release of serotonin or dopamine, and accordingly, does not produce amphetamine-like responses in animals in drug discrimination studies. Instead, MMDA-2 is likely to act as a pure 5-HT₂ receptor agonist similarly to the DOx series of compounds, with activation of the 5-HT_2A receptor conferring its psychedelic effects. MMDA-2 has been sold as a

designer drug A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. D ...

in Japan.

References

External links

Erowid - PiHKAL entry for MMDA-2

Isomerdesign - PiHKAL entry for MMDA-2
{{Phenethylamines Substituted amphetamines Designer drugs Benzodioxoles Entactogens and empathogens Serotonin receptor agonists Phenol ethers